Jenna Burton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3303366/publications.pdf

Version: 2024-02-01

535685 511568 35 981 17 30 h-index citations g-index papers 35 35 35 1111 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Retrospective immunohistochemical investigation of suspected non-visceral leiomyosarcoma in dogs. Journal of Veterinary Diagnostic Investigation, 2022, 34, 465-473.	0.5	1
2	Inhaled recombinant human IL-15 in dogs with naturally occurring pulmonary metastases from osteosarcoma or melanoma: a phase 1 study of clinical activity and correlates of response., 2022, 10, e004493.		10
3	Evaluation of accuracy for ¹⁸ Fâ€FDG positron emission tomography and computed tomography for detection of lymph node metastasis in canine oral malignant melanoma. Veterinary and Comparative Oncology, 2021, 19, 463-472.	0.8	8
4	Veterinary <scp>Cooperative < /scp> Oncology Groupâ€"Common Terminology Criteria for Adverse Events (<scp>VCOG TCAE < /scp> v2) following investigational therapy in dogs and cats. Veterinary and Comparative Oncology, 2021, 19, 311-352.</scp></scp>	0.8	117
5	Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs. Clinical Cancer Research, 2021, 27, 3005-3016.	3.2	26
6	Retrospective Evaluation of Acute Kidney Injury After Zoledronic Acid Administration to Dogs With Malignant Osteolysis. Frontiers in Veterinary Science, 2021, 8, 647846.	0.9	5
7	Lower urinary tract transitional cell carcinoma in cats: Clinical findings, treatments, and outcomes in 118 cases. Journal of Veterinary Internal Medicine, 2020, 34, 274-282.	0.6	15
8	Use of transrectal ultrasonography for assessment of the size and location of prostatic carcinoma in dogs. American Journal of Veterinary Research, 2019, 80, 1012-1019.	0.3	7
9	Metastatic immune infiltrates correlate with those of the primary tumour in canine osteosarcoma. Veterinary and Comparative Oncology, 2019, 17, 242-252.	0.8	15
10	Gender Imbalance in Authorship ofÂVeterinary Literature: 1995 versusÂ2015. Journal of Veterinary Medical Education, 2019, 46, 429-437.	0.4	5
11	Patient characteristics, prognostic factors and outcome of dogs with highâ€grade primary mediastinal lymphoma. Veterinary and Comparative Oncology, 2018, 16, E45-E51.	0.8	15
12	Retrospective analysis of doxorubicin and prednisone as first-line therapy for canine B-cell lymphoma. BMC Veterinary Research, 2018, 14, 356.	0.7	13
13	Association of surgical approach with complication rate, progression-free survival time, and disease-specific survival time in cats with mammary adenocarcinoma: 107 cases (1991–2014). Journal of the American Veterinary Medical Association, 2018, 252, 1393-1402.	0.2	21
14	NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma. Clinical Cancer Research, 2018, 24, 5830-5840.	3.2	36
15	In vitro and in vivo activity of liposomeâ €e ncapsulated curcumin for naturally occurring canine cancers. Veterinary and Comparative Oncology, 2018, 16, 571-579.	0.8	14
16	Association of cancer-related mortality, age and gonadectomy in golden retriever dogs at a veterinary academic center (1989-2016). PLoS ONE, 2018, 13, e0192578.	1.1	45
17	Clinical presentation, treatment and outcome in 31 dogs with presumed primary colorectal lymphoma (2001-2013). Veterinary and Comparative Oncology, 2017, 15, 504-517.	0.8	12
18	Potency and stability of compounded formulations of chlorambucil, melphalan and cyclophosphamide. Veterinary and Comparative Oncology, 2017, 15, 1558-1563.	0.8	10

#	Article	IF	CITATIONS
19	Expression of Phosphorylated KIT in Canine Mast Cell Tumor. Veterinary Pathology, 2017, 54, 387-394.	0.8	11
20	BCL2 and MYC are expressed at high levels in canine diffuse large B ell lymphoma but are not predictive for outcome in dogs treated with CHOP chemotherapy. Veterinary and Comparative Oncology, 2017, 15, 1269-1279.	0.8	18
21	Frequency and Severity of Neutropenia Associated with Food and Drug Administration Approved and Compounded Formulations of Lomustine in Dogs with Cancer. Journal of Veterinary Internal Medicine, 2016, 30, 242-246.	0.6	19
22	Chemotherapy effectiveness and mortality prediction in surgically treated osteosarcoma dogs: A validation study. Preventive Veterinary Medicine, 2016, 125, 126-134.	0.7	3
23	A Comparative Oncology Study of Iniparib Defines Its Pharmacokinetic Profile and Biological Activity in a Naturally-Occurring Canine Cancer Model. PLoS ONE, 2016, 11, e0149194.	1.1	19
24	Pulseâ€Administered Toceranib Phosphate Plus Lomustine for Treatment of Unresectable Mast Cell Tumors in Dogs. Journal of Veterinary Internal Medicine, 2015, 29, 1098-1104.	0.6	19
25	Abstract 4517: Plasma and tumor pharmacokinetics of IV LMP744, a novel indenoisoquinoline topoisomerase I inhibitor, in a canine phase I study. , 2015, , .		0
26	Flow Cytometric Characterization and Clinical Outcome of <scp>CD</scp> 4+ Tâ€Cell Lymphoma in Dogs: 67 Cases. Journal of Veterinary Internal Medicine, 2014, 28, 538-546.	0.6	59
27	Clinical outcome in 20 cases of lingual hemangiosarcoma in dogs: 1996–2011. Veterinary and Comparative Oncology, 2014, 12, 198-204.	0.8	21
28	Comparison of Carboplatin and Doxorubicinâ€Based Chemotherapy Protocols in 470 Dogs after Amputation for Treatment of Appendicular Osteosarcoma. Journal of Veterinary Internal Medicine, 2014, 28, 554-563.	0.6	118
29	Phase <scp>II</scp> Evaluation of <scp>VDC</scp> â€1101 in Canine Cutaneous Tâ€Cell Lymphoma. Journal of Veterinary Internal Medicine, 2014, 28, 1569-1574.	0.6	27
30	The Role of Clinical Trials in Veterinary Oncology. Veterinary Clinics of North America - Small Animal Practice, 2014, 44, 977-987.	0.5	13
31	Abstract A26: Monocyte depletion to amplify tumor vaccine immunity in a dog non-Hodgkin lymphoma model. , 2014, , .		0
32	Retrospective evaluation of doxorubicin–piroxicam combination for the treatment of transitional cell carcinoma in dogs. Journal of Small Animal Practice, 2013, 54, 67-74.	0.5	38
33	Evaluation of a 15â€week <scp>CHOP</scp> protocol for the treatment of canine multicentric lymphoma. Veterinary and Comparative Oncology, 2013, 11, 306-315.	0.8	57
34	Lowâ€Dose Cyclophosphamide Selectively Decreases Regulatory T Cells and Inhibits Angiogenesis in Dogs with Soft Tissue Sarcoma. Journal of Veterinary Internal Medicine, 2011, 25, 920-926.	0.6	98
35	Decreased Ratio of CD8+ T Cells to Regulatory T Cells Associated with Decreased Survival in Dogs with Osteosarcoma. Journal of Veterinary Internal Medicine, 2010, 24, 1118-1123.	0.6	86